OCULAR THERAPEUTIX, INC (OCUL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 25M 50M 75M Q3 '21: 38.6M Q4 '21: 43.5M Q1 '22: 49.4M Q2 '22: 49.9M Q3 '22: 49.7M Q4 '22: 51.5M Q1 '23: 51.7M Q2 '23: 54.6M Q3 '23: 57.7M Q4 '23: 58.4M Q1 '24: 59.8M Q2 '24: 61.1M Q3 '24: 61.4M Q4 '24: 63.7M Q1 '25: 59.6M Q2 '25: 56.7M Q3 '25: 55.8M Q4 '25: 52M Q1 '26: 52M Q2 '26: 52.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 20M 40M 60M Q3 '21: 34.6M Q4 '21: 39.1M Q1 '22: 44.6M Q2 '22: 45M Q3 '22: 45.1M Q4 '22: 47M Q1 '23: 47.2M Q2 '23: 50M Q3 '23: 52.8M Q4 '23: 53.2M Q1 '24: 54.4M Q2 '24: 55.5M Q3 '24: 55.7M Q4 '24: 58.1M Q1 '25: 54.1M Q2 '25: 50.7M Q3 '25: 49.6M Q4 '25: 45.4M Q1 '26: 45.4M Q2 '26: 45.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '21: -74.3M Q4 '21: -78M Q1 '22: -75.6M Q2 '22: -75.3M Q3 '22: -77.3M Q4 '22: -78.7M Q1 '23: -83.4M Q2 '23: -84M Q3 '23: -81.7M Q4 '23: -82.4M Q1 '24: -91.5M Q2 '24: -114.5M Q3 '24: -141.3M Q4 '24: -171.8M Q1 '25: -204.1M Q2 '25: -228.1M Q3 '25: -250.8M Q4 '25: -270M Q1 '26: -299.4M Q2 '26: -313.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '21: -88.3M Q4 '21: -6.6M Q1 '22: -22.2M Q2 '22: -32.5M Q3 '22: -59.3M Q4 '22: -71M Q1 '23: -88.8M Q2 '23: -90.7M Q3 '23: -67.1M Q4 '23: -80.7M Q1 '24: -115.3M Q2 '24: -138.4M Q3 '24: -174.3M Q4 '24: -193.5M Q1 '25: -192.7M Q2 '25: -216.7M Q3 '25: -249.7M Q4 '25: -265.9M Q1 '26: -290.5M Q2 '26: -301.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 2.5M 5M 7.5M Q3 '21: 4M Q4 '21: 4.4M Q1 '22: 4.8M Q2 '22: 4.9M Q3 '22: 4.6M Q4 '22: 4.5M Q1 '23: 4.5M Q2 '23: 4.6M Q3 '23: 4.9M Q4 '23: 5.3M Q1 '24: 5.4M Q2 '24: 5.6M Q3 '24: 5.8M Q4 '24: 5.6M Q1 '25: 5.6M Q2 '25: 6M Q3 '25: 6.2M Q4 '25: 6.6M Q1 '26: 6.6M Q2 '26: 6.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q3 '21: -56.6M Q4 '21: -65.5M Q1 '22: -66.8M Q2 '22: -57.6M Q3 '22: -57.8M Q4 '22: -59.6M Q1 '23: -61M Q2 '23: -70.2M Q3 '23: -64.7M Q4 '23: -70.2M Q1 '24: -84.1M Q2 '24: -88.9M Q3 '24: -117.7M Q4 '24: -134.7M Q1 '25: -145.5M Q2 '25: -175.9M Q3 '25: -190.1M Q4 '25: -204.9M Q1 '26: -226.2M Q2 '26: -238.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q3 '21: -57.5M Q4 '21: -66.7M Q1 '22: -68.1M Q2 '22: -59.3M Q3 '22: -60M Q4 '22: -63.3M Q1 '23: -67.8M Q2 '23: -78.5M Q3 '23: -72.5M Q4 '23: -76.3M Q1 '24: -87.1M Q2 '24: -90.6M Q3 '24: -119.2M Q4 '24: -136M Q1 '25: -148.4M Q2 '25: -179.4M Q3 '25: -199.4M Q4 '25: -216.9M Q1 '26: -240.9M Q2 '26: -255.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q1 '20: 51.9M Q2 '20: 57.4M Q3 '20: 68.8M Q1 '21: 87.2M Q2 '21: 82.1M Q3 '21: 85.4M Q1 '22: 82.5M Q2 '22: 82.5M Q3 '22: 77M Q1 '23: 77.4M Q2 '23: 78M Q3 '23: 85.1M Q1 '24: 132M Q2 '24: 165.8M Q3 '24: 167M Q1 '25: 169.4M Q2 '25: 172.6M Q3 '25: 183.9M Q1 '26: 224.1M Q2 '26: 225M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q1 '19: -1.62 Q2 '19: -1.82 Q3 '19: -1.89 Q4 '19: -2.00 Q1 '20: -1.96 Q2 '20: -2.03 Q3 '20: -1.79 Q4 '20: -2.60 Q3 '22: -1.01 Q4 '22: -1.02 Q1 '23: -1.19 Q2 '23: -1.20 Q3 '24: -1.22 Q4 '24: -1.25 Q1 '25: -1.14 Q2 '25: -1.27 Q3 '25: -1.43 Q4 '25: -1.42 Q1 '26: -1.44 Q2 '26: -1.40 Q2 '19 Q1 '20 Q4 '20 Q1 '23 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.